Australia - Telix Pharmaceuticals Limited (ASX: TLX, 'Telix', the 'Company') announces today it has entered an exclusive scientific and clinical research collaboration with Paris-based Mauna Kea Technologies ('Mauna Kea'), a leading medical device company pioneering the development of real-time intra-operative endomicroscopic visualisation of cancer tissue.

The parties will work together to develop advanced image-guided surgical technologies in the field of urologic oncology.

The focus of the collaboration, which has been named the 'Imaging and Robotics in Surgery' ('IRiS') Alliance, is to combine the use of Telix's dual-modality positron emission tomography ('PET') tracers that deliver concurrent PET and fluorescent (optical) imaging, with Mauna Kea's Cellvizio confocal laser endomicroscopy (CLE) in vivo cellular imaging platform. The clinical objective is to enable the urologic surgeon to access real-time visualisation of cancer tissues in the operating theatre in a manner that can be directly correlated to pre-operative PET imaging. The IRiS Alliance aims to develop advanced capabilities for pre-operative planning, intra-operative guidance, surgical margin assessment and other surgical parameters, with initial applications in prostate and renal (kidney) cancer.

Telix CEO Dr. Christian Behrenbruch said, 'The cutting-edge techniques our respective companies have developed in molecular targeting and real-time in vivo cellular imaging have a natural synergy and we are delighted to have formalised this ground-breaking partnership. Through the IRiS Alliance, Telix and Mauna Kea together aim to deliver significant improvements in surgical techniques and clinical outcomes in patients with urologic malignancies, with the ultimate objective of improving the lives of the patients we serve.'

Mauna Kea Technologies CEO Robert L. Gershon stated, 'We are excited to announce this exclusive scientific and clinical research collaboration with Telix in the field of urologic oncology. The IRiS Alliance endeavors to combine the strengths of Telix's molecular targeting with Cellvizio's realtime in vivo cellular imaging to bring dual-modality molecular imaging to the operating theatre for the first time. The IRiS Alliance aims to significantly transform how the urologic surgeon will evaluate, target, excise, and confirm surgical margins at the cellular level. Our collaboration will further empower surgeons to fight cancers and save lives.'

About Telix Pharmaceuticals Limited

Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical need in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX).

About Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company focused on eliminating uncertainties related to the diagnosis and treatment of cancer and other diseases thanks to real time in vivo microscopic visualization. The Company's flagship product, Cellvizio, has received clearance/approval in a wide range of applications in more than 40 countries, including the United States, Europe, Japan, and China.

Contact:

Dr. Christian Behrenbruch

Email: chris@telixpharma.com

(C) 2020 Electronic News Publishing, source ENP Newswire